Genomic and Epigenomic Profile of Thyroid Cancer
Overview
Affiliations
Thyroid cancer is the most common malignancy of the endocrine system, and its incidence has been steadily increasing. Advances in sequencing have allowed analysis of the entire cancer genome, and has provided new information on the genetic lesions and modifications responsible for the onset, progression, dedifferentiation and metastasis of thyroid carcinomas. Moreover, integrated genomics has advanced our understanding of the development of cancer and its behavior, and has facilitated the identification of new genetic mutations and molecular pathways. The functional analysis of epigenetic modifications, such as DNA methylation, histone acetylation and non-coding RNAs, have contributed to define new regulatory mechanisms that control cell malignancy in thyroid cancer, especially aggressive forms. Here we review the most recent advances in genomics and epigenomics of thyroid cancer, which have resulted in a new classification and interpretation of the initiation and progression of thyroid tumors, providing new tools and opportunities for further investigation and for the clinical development of new treatment strategies.
Advanced pathological subtype classification of thyroid cancer using efficientNetB0.
Guo H, Zhang J, Li Y, Pan X, Sun C Diagn Pathol. 2025; 20(1):28.
PMID: 40055769 PMC: 11887243. DOI: 10.1186/s13000-025-01621-6.
Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.
Hartmann H, Loberg M, Xu G, Schwarzkopf A, Chen S, Phifer C Endocrinology. 2025; 166(3).
PMID: 39951495 PMC: 11843548. DOI: 10.1210/endocr/bqaf030.
Sabi E Front Oncol. 2024; 14:1474267.
PMID: 39558949 PMC: 11570407. DOI: 10.3389/fonc.2024.1474267.
Belaiche A, Morand G, Turkdogan S, Kang E, Forest V, Pusztaszeri M Curr Oncol. 2024; 31(10):5919-5928.
PMID: 39451745 PMC: 11506192. DOI: 10.3390/curroncol31100441.
Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).
PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.